Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Renal Artery Stent with Protective Device/Drug · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Renal Artery Stent with Protective Device/Drug | DEVICE | - |
Inclusion Criteria: Any one or more of the following: Meet Angiographic criteria plus * Systemic hypertension at baseline, or a history of hypertension * Congestive heart failure at baseline, or a history of CHF * Renal insufficiency at baseline, or a history of renal insufficiency * Angina, or a...
Renal Artery Stent with Protective Device/Drug is used for renal artery stenosis, a narrowing of the arteries that supply blood to the kidneys. It is an investigational device being studied in a Phase 2 clinical trial to evaluate stenting with or without distal protection in patients with this condition.
Johnson & Johnson (NYSE: JNJ) is developing Renal Artery Stent with Protective Device/Drug. The company is conducting a Phase 2 clinical trial of this investigational device for renal artery stenosis.
Renal Artery Stent with Protective Device/Drug is in Phase 2 clinical development. It is an investigational device, not yet approved by the FDA, and is being studied in a completed Phase 2 trial for renal artery stenosis.
Renal Artery Stent with Protective Device/Drug has one completed Phase 2 trial, NCT00234585, titled 'Prospective Randomized Study Comparing Renal Artery Stenting (RESIST) With/Without Distal Protection.' The trial enrolled 100 participants with renal artery stenosis in the United States.
Yes, the Phase 2 trial of Renal Artery Stent with Protective Device/Drug (NCT00234585) was randomized and double-blind. However, it used an uncontrolled design, meaning there was no active comparator or placebo control group.